Rosuvastatin enhances alterations caused by Toxoplasma gondii in the duodenum of mice

Tissue Cell. 2023 Oct:84:102194. doi: 10.1016/j.tice.2023.102194. Epub 2023 Aug 8.

Abstract

Infection by Toxoplasma gondii may compromise the intestinal histoarchitecture through the tissue reaction triggered by the parasite. Thus, this study evaluated whether treatment with rosuvastatin modifies duodenal changes caused by the chronic infection induced by cysts of T. gondii. For this, female Swiss mice were distributed into infected and treated group (ITG), infected group (IG), group treated with 40 mg/kg rosuvastatin (TG) and control group (CG). After 72 days of infection, the animals were euthanized, the duodenum was collected and processed for histopathological analysis. We observed an increase in immune cell infiltration in the IG, TG and ITG groups, with injury to the Brunner glands. The infection led to a reduction in collagen fibers and mast cells. Infected and treated animals showed an increase in collagen fibers, acidic mucin-producing goblet cells, intraepithelial lymphocytes and mast cells, in addition to the reduction of muscle, neutral mucin-producing and Paneth cells. While treatment with rosuvastatin alone led to increased muscle layer, proportion of neutral mucin-producing goblet cells, Paneth cells, and reduction of collagen fibers. These findings indicate that the infection and treatment caused changes in the homeostasis of the intestinal wall and treatment with rosuvastatin potentiated most parameters indicative of inflammation.

Keywords: Inflammatory response; Small intestine; Statin; Toxoplasmosis.

MeSH terms

  • Animals
  • Collagen
  • Duodenum
  • Female
  • Mice
  • Mucins
  • Rosuvastatin Calcium / pharmacology
  • Rosuvastatin Calcium / therapeutic use
  • Toxoplasma*

Substances

  • Rosuvastatin Calcium
  • Mucins
  • Collagen